Search Result

Results for "

Insulin receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	IGF-1R (21) Insulin Receptor (40) 5-HT Receptor (1) Adenosine Kinase (1) Adenosine Receptor (2) Adenylate Cyclase (2) Adrenergic Receptor (2) Akt (2) Amylin Receptor (1) Anaplastic lymphoma kinase (ALK) (3) Androgen Receptor (1) Angiotensin Receptor (1) Apelin Receptor (APJ) (1) Apoptosis (10) Autophagy (5) Calcium Channel (1) CGRP Receptor (2) Cholecystokinin Receptor (1) CRFR (1) EGFR (1) Endogenous Metabolite (1) ERK (1) FAK (1) FGFR (1) Free Fatty Acid Receptor (9) FXR (1) G protein-coupled Bile Acid Receptor 1 (1) G Protein-coupled Receptor Kinase (GRK) (2) GCGR (4) GHR (2) GLP Receptor (5) Glucocorticoid Receptor (3) Glucosidase (1) GLUT (2) GnRH Receptor (3) Histamine Receptor (1) HIV (1) Isotope-Labeled Compounds (2) Itk (1) JAK (1) mAChR (1) MCHR1 (GPR24) (1) Neuropeptide Y Receptor (3) NF-κB (2) Opioid Receptor (1) p38 MAPK (2) PDGFR (1) PGC-1α (1) Phosphatase (2) PKA (1) Potassium Channel (1) PPAR (3) PTEN (1) Pyk2 (1) RXFP Receptor (1) Small Interfering RNA (siRNA) (2) Somatostatin Receptor (5) STAT (1) Taste Receptor (1) Tie (1) TRP Channel (1) Tyrosinase (1) VEGFR (1)
By Research Areas:	Cancer (30) Cardiovascular Disease (10) Endocrinology (26) Infection (1) Inflammation/Immunology (15) Metabolic Disease (76) Neurological Disease (9)
Oligonucleotides:	Antisense Oligonucleotides (4)

126

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Uralenol	Phosphatase	Metabolic Disease
Uralenol is a natural PTP1B inhibitor (IC₅₀=21. 5 μM) from Broussonetia papyrifera. PTP1B have been shown to play a major role in the dephosphorylation of the insulin receptor in many cellular and biochemical studies .

Demethylasterriquinone B1 DAQ B1; L-783281; Dimethylasterriquinone	Insulin Receptor Akt	Endocrinology
Demethylasterriquinone B1 is a selective **insulin receptor activator. Demethylasterriquinone B1 stimulates tyrosine phosphorylation of the IR β subunit, and the activation of PIK3 and AKT** .

HNMPA-(AM)3	Insulin Receptor	Metabolic Disease
HNMPA-(AM)3 is a cell-permeable and selective insulin receptor tyrosine kinase inhibitor analog of HNMPA. HNMPA-(AM)3 greatly inhibits the ability of prothoracicotropic hormone (PTTH) to activate ERK phosphorylation and stimulate ecdysteroidogenesis. HNMPA-(AM)3 is also effective in inhibiting ecdysteroid production (IC₅₀=14.2 μM) and insulin receptor activity (IC₅₀ is 14.2 μM and 200 μM in mosquitoes and mammals, respectively) .

GRK5-IN-2	G Protein-coupled Receptor Kinase (GRK)	Metabolic Disease
GRK5-IN-2 (compound 707), a pyridine-based bicyclic compound, is a potent *G-protein-coupled receptor* kinase 5 (GRK5)** inhibitor. GRK5-IN-2 regulates the expression and/or release of insulin and is useful for the metabolic disease research .

AGL-2263 1 Publications Verification	Insulin Receptor	Metabolic Disease Endocrinology
AGL-2263 is an **insulin receptor and insulin-like growth factor (IGF) receptor** inhibitor .

*[pTyr1146][pTyr1150][pTyr1151]Insulin* Receptor (1142-1153)**	Insulin Receptor	Metabolic Disease
[pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153) binds to insulin and can be used as insulin receptor tyrosine kinase substrates .

BpV(pic) potassium hydrate	PTEN	Metabolic Disease
BpV(pic) potassium hydrate is a PTEN inhibitor with IC₅₀ 31 nM. BpV(pic) potassium hydrate is also an insulin simulator that activates insulin receptor kinase in cultured liver cancer cells, stimulates adipogenesis in adipocytes, and inhibits the dephosphorylation of autophosphorylated insulin receptors and epidermal growth factor receptors in rat hepatosomes .

HNMPA	Insulin Receptor	Metabolic Disease
HNMPA is a membrane impermeable insulin receptor tyrosine kinase inhibitor. HNMPA inhibits serine and tyrosine autophosphorylation by the human insulin receptor. HNMPA has no effect on protein kinase C or cyclic AMP-dependent protein kinase activities

ERK Inhibitor II (Negative control)	ERK Insulin Receptor	Metabolic Disease
ERK Inhibitor II (Negative control) is an effective inhibitor of extracellular signal-regulated kinase (ERK). ERK Inhibitor II (Negative control) inhibits the activation of **insulin receptor**, which can be used in the study of diabetes .

MY17	Phosphatase	Metabolic Disease
MY17 is an inhibitor of protein tyrosine phosphatase 1B (PTP1B) (IC₅₀=0.41±0.05 μM). MY17 alleviates palmitic acid (PA) -induced insulin resistance by up-regulating the expression of phosphorylated insulin receptor substrate (IRS1) and protein kinase B (AKT). By binding with PTP1B, MY17 can inhibit the activity of PTP1B, thereby improving insulin signaling and having anti-diabetic activity. MY17 can be used in the study of type 2 diabetes .

Des His1, Glu8 Exendin-4	GCGR	Metabolic Disease
Des His1, Glu8 Exendin-4 is a potent *glucagon-like peptide-1 receptor* (GLP-1-R)** antagonist. Des His1, Glu8 Exendin-4 improves glucose homeostasis by regulating both insulin secretion and glucose production. Des His1, Glu8 Exendin-4 can be used for the research of type 2 diabetic and gastrointestinal .

LY2881835	Free Fatty Acid Receptor	Endocrinology
LY2881835 is a potent and selective agonist of G protein-coupled receptor 40 (GPR40). LY2881835 has efficacious and durable dose-dependent reductions in glucose levels along with significant increases in insulin and GLP-1 secretion. LY2881835 has the potential for the research of type 2 diabetes mellitus . LY2881835 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

TLK19781	Others	Others
TLK19781 is a non-peptide small molecule insulin receptor activator that increases the content of insulin-stimulated GLUT4 on the cell membrane and enhances the activity of insulin-stimulated glucose transport in cell and animal models of insulin resistance.

Insulin degludec	Insulin Receptor	Endocrinology
Insulin degludec is an ultra-long-acting form of *insulin* used for the research of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC₅₀ value of 19.59 nM for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes .

Insulin degludec (Standard)	Insulin Receptor	Endocrinology
Insulin degludec (Standard) is the analytical standard of Insulin degludec. This product is intended for research and analytical applications. Insulin degludec is an ultra-long-acting form of *insulin* used for the research of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC₅₀ value of 19.59 nM for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes .

INSR agonist 1	Insulin Receptor	Metabolic Disease
INSR agonist 1 is an insulin receptor (INSR) agonist. INSR agonist 1 can increase INSR pY1355/1361 levels and works synergistically with insulin .

S961	Insulin Receptor	Metabolic Disease
S961 is an high-affinity and selective **insulin receptor (IR) antagonist with IC₅₀*s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor* (HIGF-IR) in SPA-assay, respectively .

S961 acetate 4 Publications Verification	Insulin Receptor	Metabolic Disease
S961 acetate is an high-affinity and selective **insulin receptor (IR) antagonist with IC₅₀*s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor* (HIGF-IR) in SPA-assay, respectively .

S961 TFA	Insulin Receptor	Metabolic Disease
S961 TFA is an high-affinity and selective **insulin receptor (IR) antagonist with IC₅₀*s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor* (HIGF-IR) in SPA-assay, respectively .

Glucocorticoids receptor agonist 1	Glucocorticoid Receptor	Inflammation/Immunology
Glucocorticoids receptor agonist 1 is a potent anti-inflammatory, arylpyrazole-based glucocorticoid receptor agonist that does not impair insulin secretion.

Glucocorticoids receptor agonist 2	Glucocorticoid Receptor	Inflammation/Immunology
Glucocorticoids receptor agonist 2 is a potent anti-inflammatory, arylpyrazole-based glucocorticoid receptor agonist that does not impair insulin secretion.

Insulin efsitora alfa LY-3209590	Insulin Receptor	Metabolic Disease
Insulin efsitora alfa (LY-3209590) is a selective agonist of insulin receptor (IR). Insulin efsitora alfa is a fusion protein composed of human IR agonists fused with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2) fragment, with a molecular weight of 64.1 kDa. Insulin efsitora alfa is well tolerated and has potential applications in diabetes .

BMS-536924 3 Publications Verification	IGF-1R Insulin Receptor Apoptosis	Endocrinology Cancer
BMS-536924 is an orally active, competitive and selective insulin-like growth factor receptor (IGF-1R) kinase and insulin receptor (IR) inhibitor with IC₅₀s of 100 nM and 73 nM, respectively. BMS-536924 has anti-cancer activity .

(Pro3) GIP, human TFA (Pro3) Gastric Inhibitory Peptide, human TFA	Insulin Receptor	Metabolic Disease
(Pro3) GIP, human TFA is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human TFA has high binding affinity for human GIPR with K_i/ K_d value of 0.90 nM. (Pro3) GIP, human TFA human can be used for the research of obesity-related diabetes .

Dextran sulfate sodium salt (MW 35000-50000) 2 Publications Verification DSS (MW 35000-50000); DXS (MW 35000-50000)	HIV Apoptosis	Infection Inflammation/Immunology
Dextran sulfate sodium salt (MW 35000-50000) is a polymer of anhydroglucose and is a potent inducer of colitis. Dextran sulfate sodium salt (MW 35000-50000) may be related to macrophage dysfunction, intestinal flora dysbiosis, and is particularly toxic to the colonic epithelium. Dextran sulfate sodium salt (MW 35000-50000) also inhibits human immunodeficiency virus replication by preventing viral adsorption to host cells. Dextran sulfate sodium salt (MW 35000-50000) is also used to bind to insulin, encapsulate it in gold nanoparticles, and serve as an insulin carrier to bind to insulin receptors to achieve the purpose of slowly releasing insulin and prolonging insulin activity .

(Sar1,Ile4,8)-Angiotensin II	Angiotensin Receptor	Metabolic Disease
(Sar1,Ile4,8)-Angiotensin II is a functionally selective *angiotensin II type 1 receptor* (AT1R)** agonist. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated insulin receptor (IR) signaling and glycogen synthesis. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated phosphorylation of Akt and GSK3α/β .

Aganirsen	Insulin Receptor	Inflammation/Immunology
Aganirsen is a 25 mer DNA antisense oligonucleotide, which silences expression of insulin receptor substrate-1 (IRS-1).

Aganirsen sodium	Insulin Receptor	Inflammation/Immunology
Aganirsen sodium is a 25 mer DNA antisense oligonucleotide, which silences expression of insulin receptor substrate-1 (IRS-1).

Linsitinib Maximum Cited Publications 38 Publications Verification OSI-906	IGF-1R Insulin Receptor	Endocrinology Cancer
Linsitinib (OSI-906) is a potent, selective and orally bioavailable dual inhibitor of the IGF-1 receptor and insulin receptor (IR) with IC₅₀s of 35 and 75 nM, respectively .

A-71915 TFA	Apoptosis	Metabolic Disease
A-71915 (TFA) is a selective inhibitor of ANP receptor (atrial natriuretic peptide-receptor), induces apoptosis and decreases insulin secretion in RINm5F pancreatic β-cells .

Lactisole	Taste Receptor	Metabolic Disease
Lactisole is a canonical antagonist of sweet taste receptor, selectively targeting to T1R3 subunit, a glucose-sensing receptor. Lactisole inhibits insulin secretion induced by glucose in mouse islets .

Picropodophyllin 15+ Cited Publications AXL1717; Picropodophyllotoxin; PPP	IGF-1R Apoptosis	Endocrinology Cancer
Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC₅₀ of 1 nM.

MID-1	Insulin Receptor	Metabolic Disease
MID-1 is a disruptor of MG53-IRS-1 (Mitsugumin 53-insulin receptor substrate-1) interaction. MID-1 disrupts molecular association of MG53 with IRS-1 and abolishes MG53-induced IRS-1 ubiquitination and degradation in skeletal muscle, leading to elevated IRS-1 expression level and increased insulin signaling and glucose uptake .

GIP (3-42), human	Insulin Receptor	Metabolic Disease
GIP (3-42), human acts as a glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist, moderating the insulin secreting and metabolic actions of GIP in vivo .

Lactisole free acid	Others	Metabolic Disease
Lactisole free acid is a canonical antagonist of sweet taste receptor, selectively targeting to T1R3 subunit, a glucose-sensing receptor. Lactisole free acid inhibits insulin secretion induced by glucose in mouse islets .

GSK1904529A 5+ Cited Publications	IGF-1R Insulin Receptor Apoptosis	Endocrinology Cancer
GSK1904529A is a potent, selective, orally active, and ATP-competitive inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), with IC₅₀s of 27 and 25 nM, respectively. GSK1904529A shows poor activity (IC₅₀>1 μM) in 45 other serine/threonine and tyrosine kinases. GSK1904529A exhibits anti-tumor activity .

BMS-194449	Adrenergic Receptor	Metabolic Disease
BMS-194449 is a beta 3 receptor agonist with the K_i value of 160 nM. BMS-194449 can be used for study of obesity and non-insulin dependent diabetes .

Gluten Exorphin B5	Opioid Receptor	Metabolic Disease
Gluten Exorphin B5 is an exogenous opioid peptides derived from wheat gluten, acts on opioid receptor, increases postprandial plasma insulin level in rats .

Axltide	JAK	Metabolic Disease
Axltide is based on the mouse Insulin receptor substrate 1 (amino acid 979-989). Axltide is a substrate for Axl, DDR2, Mst1, and JAK2 kinases .

Voglibose	Glucosidase	Metabolic Disease
Voglibose is an orally active alpha-glucosidase inhibitor that prevents the development of colorectal precancerous lesions induced by obesity and diabetes. Voglibose reduces oxidative stress in an inflammatory environment and inhibits the insulin-like growth factor/insulin-like growth factor-1 receptor (IGF/IGF-1R) functional axis .

Ganglioside GM3	Others	Metabolic Disease
Ganglioside GM3 is a precursor of a-, b-, and c-series gangliosides, interacts with transmembrane receptors such as the epidermal growth factor and insulin receptors, and regulates receptor functions by creating a specialized lipid environment. Ganglioside GM3 is synthesized by GM3 synthase and can be used for the research of hypercholesterolemia .

Glucocorticoid receptor agonist 1 Publications Verification	Glucocorticoid Receptor	Metabolic Disease Inflammation/Immunology Endocrinology
Glucocorticoid receptor agonist is a Glucocorticoid receptor agonist that acts on Glucocorticoid receptor (GR), progesterone receptor (PR) and mineralocorticoid receptor (MR) with the IC₅₀ values of 2.1 , 1200 and 210 nM, respectively. Glucocorticoid receptor agonist has steroid-like anti-inflammatory properties and may be used to improve metabolism and reduce increased levels of body fat and serum insulin .

Indirubin Derivative E804	IGF-1R	Endocrinology Cancer
Indirubin Derivative E804 is a potent inhibitor of Insulin-like Growth Factor 1 Receptor (IGF1R), with an IC₅₀ of 0.65 μM for IGF1R.

ML-290	RXFP Receptor	Others
ML-290 is a first-in-class and potent relaxin/insulin-like family peptide receptor (RXFP1) agonist and activator of anti-fibrotic genes, with an EC₅₀ of 94 nM . ML290 is a biased allosteric agonist at the relaxin receptor RXFP1.

GSK1838705A 5+ Cited Publications	Anaplastic lymphoma kinase (ALK) IGF-1R Insulin Receptor	Endocrinology Cancer
GSK1838705A is a potent and reversible IGF-IR and the **insulin receptor inhibitor with IC₅₀s of 2.0 and 1.6 nM, respectively. It also inhibits ALK with an IC₅₀** of 0.5 nM.

DA-JC4	Insulin Receptor	Neurological Disease Inflammation/Immunology
DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways .

Cat. No.	Product Name

HY-L016

Protein Tyrosine Kinase Compound Library

1,140 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 1,140 compounds that act as a useful tool for PTKs-related drug screening and disease research.

HY-L040

Anti-diabetic Compound Library

793 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 793 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Cat. No.	Product Name	Type

HY-W011012

Adenosine 5'-monophosphate disodium

5+ Cited Publications

Enzyme Substrates

Adenosine 5'-monophosphate disodium is an orally active purine nucleotide, and participates in ATP metabolism. Adenosine 5'-monophosphate disodium is also a ligand for adenosine 2B receptor. Adenosine 5'-monophosphate disodium can activate AMPK in skeletal muscle, and ameliorates insulin resistance and impaired glucose metabolism. Adenosine 5'-monophosphate disodium can be used for research of diabetes .

Cat. No.	Product Name	Target	Research Area

HY-P5431

Insulin receptor (1142-1153), pTyr1150	Peptides	Others
Insulin receptor (1142-1153), pTyr1150 is a biological active peptide. (Peptide used as insulin receptor tyrosine kinase substrate.)

HY-108743

Insulin degludec	Insulin Receptor	Endocrinology
Insulin degludec is an ultra-long-acting form of *insulin* used for the research of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC₅₀ value of 19.59 nM for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes .

HY-P2093B

S961 acetate 4 Publications Verification	Insulin Receptor	Metabolic Disease
S961 acetate is an high-affinity and selective **insulin receptor (IR) antagonist with IC₅₀*s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor* (HIGF-IR) in SPA-assay, respectively .

HY-P3584A

(Pro3) GIP, human TFA (Pro3) Gastric Inhibitory Peptide, human TFA	Insulin Receptor	Metabolic Disease
(Pro3) GIP, human TFA is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human TFA has high binding affinity for human GIPR with K_i/ K_d value of 0.90 nM. (Pro3) GIP, human TFA human can be used for the research of obesity-related diabetes .

HY-P1776

*[pTyr1146][pTyr1150][pTyr1151]Insulin* Receptor (1142-1153)**	Insulin Receptor	Metabolic Disease
[pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153) binds to insulin and can be used as insulin receptor tyrosine kinase substrates .

HY-P3542

Des His1, Glu8 Exendin-4	GCGR	Metabolic Disease
Des His1, Glu8 Exendin-4 is a potent *glucagon-like peptide-1 receptor* (GLP-1-R)** antagonist. Des His1, Glu8 Exendin-4 improves glucose homeostasis by regulating both insulin secretion and glucose production. Des His1, Glu8 Exendin-4 can be used for the research of type 2 diabetic and gastrointestinal .

HY-108743R

Insulin degludec (Standard)	Insulin Receptor	Endocrinology
Insulin degludec (Standard) is the analytical standard of Insulin degludec. This product is intended for research and analytical applications. Insulin degludec is an ultra-long-acting form of *insulin* used for the research of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC₅₀ value of 19.59 nM for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes .

HY-P2093

S961	Insulin Receptor	Metabolic Disease
S961 is an high-affinity and selective **insulin receptor (IR) antagonist with IC₅₀*s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor* (HIGF-IR) in SPA-assay, respectively .

HY-P2093A

S961 TFA	Insulin Receptor	Metabolic Disease
S961 TFA is an high-affinity and selective **insulin receptor (IR) antagonist with IC₅₀*s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor* (HIGF-IR) in SPA-assay, respectively .

HY-P5433F

IRS-1 Peptide, FAM labeled	Peptides	Others
IRS-1 Peptide, FAM labeled is a biological active peptide. (Insulin receptor substrate)

HY-P4685

(Sar1,Ile4,8)-Angiotensin II	Angiotensin Receptor	Metabolic Disease
(Sar1,Ile4,8)-Angiotensin II is a functionally selective *angiotensin II type 1 receptor* (AT1R)** agonist. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated insulin receptor (IR) signaling and glycogen synthesis. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated phosphorylation of Akt and GSK3α/β .

HY-P5487

GluR23Y	Peptides	Others
GluR23Y is a biological active peptide. (This GluR23Y peptide was used in ELISA cell-surface assay for the insulin-stimulated endocytosis of native AMPA receptors in cultured hippocampal neurons. GluR23Y prevented any insulin-induced reduction. The blockade of insulin action was observed when the GluR23Y peptide was delivered into neurons by fusing it to the membrane transduction domain of HIV-1.)

HY-P1980

A-71915 TFA	Apoptosis	Metabolic Disease
A-71915 (TFA) is a selective inhibitor of ANP receptor (atrial natriuretic peptide-receptor), induces apoptosis and decreases insulin secretion in RINm5F pancreatic β-cells .

HY-P2542

GIP (3-42), human	Insulin Receptor	Metabolic Disease
GIP (3-42), human acts as a glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist, moderating the insulin secreting and metabolic actions of GIP in vivo .

HY-P1742

Gluten Exorphin B5	Opioid Receptor	Metabolic Disease
Gluten Exorphin B5 is an exogenous opioid peptides derived from wheat gluten, acts on opioid receptor, increases postprandial plasma insulin level in rats .

HY-P1790

Axltide	JAK	Metabolic Disease
Axltide is based on the mouse Insulin receptor substrate 1 (amino acid 979-989). Axltide is a substrate for Axl, DDR2, Mst1, and JAK2 kinases .

HY-P3255

DA-JC4	Insulin Receptor	Neurological Disease Inflammation/Immunology
DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways .

HY-P1473

Amylin (8-37), rat Amylin (8-37) (mouse, rat)	Amylin Receptor	Metabolic Disease
Amylin (8-37), rat is a truncated analog of native Amylin that selectively inhibits insulin-related glucose uptake and glycogen deposition in muscle tissue. Amylin (8-37), rat is a weak amylin receptor (AMY) antagonist.

HY-P3954

Somatostatin-28 (sheep, human rat mouse)	Somatostatin Receptor	Metabolic Disease
Somatostatin-28 (sheep, human rat mouse) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep, human rat mouse) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep, human rat mouse) also targets to *somatostatin receptor* subtype 5 (SSTR5**) to regulate GLP-1 secretion .

HY-108905

Mecasermin Human IGF-I; FK 780	IGF-1R	Metabolic Disease
Mecasermin (Human IGF-I; FK 780) is a recombinant human insulin-like growth factor I (IGF-I). Mecasermin has the potential for the study of the growth failure of growth hormone (GH) insensitivity caused by GH receptor defects or GH-inhibiting antibodies .

HY-P2541

GIP (1-30) amide, porcine	Insulin Receptor	Metabolic Disease
GIP (1-30) amide, porcine is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42) . GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.

HY-P5433

IRS1-derived peptide	Peptides	Others
IRS1-derived peptide is a biological active peptide. (This is a peptide fragment (979-989) of the insulin receptor substrate-1 containing the sequence motif YMXM known to bind to the two domains of SH2 on the 85kDa subunit of phosphoinositide 3-kinase.)

HY-P2541A

GIP (1-30) amide, porcine TFA 1 Publications Verification	Insulin Receptor	Metabolic Disease
GIP (1-30) amide, porcine TFA is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42) . GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.

HY-P10318

SHR-2042	GLP Receptor	Endocrinology
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .

HY-P10302

GLP-1R/GIPR agonist-1	GLP Receptor Insulin Receptor	Metabolic Disease
GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-P1072

PHM-27 (human)	CGRP Receptor	Cardiovascular Disease Metabolic Disease
PHM-27 (human) is a human prepro-vasoactive intestinal polypeptide (27 amino acid). PHM-27 (human) is a potent the human calcitonin receptor agonist with an EC₅₀ of 11 nM. PHM-27 (human) efficiently enhances glucose-induced insulin secretion from beta cells by an autocrine mechanism .

HY-119152

CMX-2043	Insulin Receptor Tyrosinase Akt	Others
CMX-2043 is a novel analogue of α-Lipoic Acid (HY-N0492). CMX-2043 is effective in antioxidant effect, activation of insulin receptor kinase, soluble tyrosine kinase, and Akt phosphorylation. CMX-2043 shows protection against ischemia-reperfusion injury (IRI) in rat model .

HY-P1434

[Pro3]-GIP (mouse)	Insulin Receptor	Metabolic Disease
[Pro3]-GIP (mouse) is a GIP receptor antagonist (IC₅₀: 2.6 μM). [Pro3]-GIP (mouse) improves glucose tolerance and insulin sensitivity in ob/ob mice. [Pro3]-GIP (mouse) can be used for research of type 2 diabetes .

HY-P0262

Galantide	Neuropeptide Y Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
Galantide, a non-specific galanin receptor antagonist, is a peptide consisting of fragments of galanin and substance P. Galantide recognizes two classes of galanin binding sites (K_D<0.1 nM and ~6 nM) in the rat hypothalamus. Galantide dose dependently (IC₅₀=1.0 nM) antagonizes the galanin-mediated inhibition of the glucose-induced insulin secretion from mouse pancreatic islets. Galantide appears to bind to a single population of SP receptors (K_D~40 nM) .

HY-P10302A

GLP-1R/GIPR agonist-1 (soduim)	GLP Receptor	Metabolic Disease
GLP-1R/GIPR agonist-1 soduim is the sodium salt form of GLP-1R/GIPR agonist-1 (HY-P10302). GLP-1R/GIPR agonist-1 soduim is a dual agonist for glucagon-like peptide-1 receptor (GLP-1R, EC₅₀ is 0.57 nM) and glucose-dependent insulin releasing peptide receptor (GIPR, EC₅₀ is 0.75 nM). GLP-1R/GIPR agonist-1 soduim lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 soduim can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-P3641

Kisspeptin 13	GnRH Receptor	Neurological Disease Metabolic Disease
Kisspeptin 13 inhibits glucose-induced insulin secretion with an IC₅₀ of 1.2 nM. Kisspeptin 13 activates the hypothalamic-pituitary-adrenal (HPA) axis, causes hyperthermia, motor behavior and anxiety in rats. Kisspeptin 13 interacts with α2-adrenergic and 5-HT2 serotonin receptors, exhibits antidepressant efficacy. Kisspeptin 13 is an activator for GPR54 and GnRH receptor, which enhances memory and can be used in Alzheimer's disease research .

HY-117483

Gly-Pro-Glu	Peptides	Neurological Disease
Gly-Pro-Glu is a neuroactive peptide with a potent action on acetylcholine release. Gly-Pro-Glu is the N-terminal tripeptide of insulin-like growth factor-I. Gly-Pro-Glu inhibits glutamate binds to N-methyl-D-aspartate (NMDA) receptor with an IC₅₀ value of 14.7 μM. Gly-Pro-Glu can be used for the research of neuroprotection .

HY-P3608

[Des-His1,Glu9] Glucagon	GCGR	Metabolic Disease
[Des-His1,Glu9] Glucagon is a potent *glucagon receptor* system** peptide antagonist. [Des-His1,Glu9] Glucagon enhances the glucose-stimulated release of insulin from pancreatic islet cells. [Des-His1,Glu9] Glucagon can be used to research diabetes .

HY-P2090

Angiopeptin	Somatostatin Receptor Adenylate Cyclase	Cardiovascular Disease
Angiopeptin, a cyclic octapeptide analogue of somatostatin, is a weak sst₂/sst₅ receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin has the potential for coronary atherosclerosis research .

HY-P2090A

Angiopeptin TFA	Somatostatin Receptor Adenylate Cyclase	Cardiovascular Disease
Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak sst₂/sst₅ receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential for coronary atherosclerosis research .

HY-P3641A

Kisspeptin 13 TFA	GnRH Receptor	Neurological Disease Metabolic Disease
Kisspeptin 13 TFA is the TFA salt form of Kisspeptin 13 (HY-P3641). Kisspeptin-13 TFA inhibits glucose-induced insulin secretion with an IC₅₀ of 1.2 nM. Kisspeptin 13 TFA activates the hypothalamic-pituitary-adrenal (HPA) axis, causes hyperthermia, motor behavior and anxiety in rats. Kisspeptin 13 TFA interacts with α2-adrenergic and 5-HT2 serotonin receptors, exhibits antidepressant efficacy. Kisspeptin 13 TFA is an activator for GPR54 and GnRH receptor, which enhances memory and can be used in Alzheimer's disease research .

HY-P10413

SHBG(141–161)	Androgen Receptor	Metabolic Disease Endocrinology
SHBG 141-161 is a GPRC6A receptor agonist. SHBG 141-161 mimics the action of GPRC6A endogenous agonist uncarboxylated osteocalcin by binding to GPRC6A and promoting downstream signaling to increase testosterone and insulin secretion. SHBG 141-161 also reduces the affinity of GPRC6A to GDP protein by binding to the outer cell domain of GPRC6A thus affecting the dynamics of signal transduction. SHBG 141-161 can be used to study GPRC6A in energy metabolism and endocrine regulation .

HY-P5762A

Phoenixin-14 TFA PNX-14 TFA	GnRH Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Phoenixin-14 (PNX-14) TFA, a BBB-penatrable neuropeptide, has anxiolytic, cardioprotective and neuroprotective effect. Phoenixin-14 TFA can regulate pituitary gonadotrophin secretion by upregulating the GnRH receptor mRNA. Phoenixin-14 TFA stimulates insulin secretion. Phoenixin-14 TFA also protects mice from ischemia/reperfusion (IR) injury. PNX-14 TFA prevents oxidative stress by reducing ROS and increasing GSH .

HY-P1128

Galanin (swine)	Neuropeptide Y Receptor	Metabolic Disease
Galanin (swine), a neuropeptide, consists of 29 amino acids and contains a C-terminal amidated glycine. Galanin (swine) inhibits basal and stimulated insulin secretion both in vivo and in vitro under a variety of experimental conditions. Galanin (swine) is a galanin receptor agonist with pK_is of 9.63, 9.49, 9.02, 8.98, 8.01 and 8.14 at human GAL1, rat GAL1, human GAL2, rat GAL2, human GAL3 and rat GAL3 respectively .

HY-P1128A

Galanin (swine) (TFA)	Neuropeptide Y Receptor	Metabolic Disease
Galanin (swine) TFA, a neuropeptide, consists of 29 amino acids and contains a C-terminal amidated glycine. Galanin (swine) inhibits basal and stimulated insulin secretion both in vivo and in vitro under a variety of experimental conditions. Galanin (swine) TFA is a galanin receptor agonist with pK_is of 9.63, 9.49, 9.02, 8.98, 8.01 and 8.14 at human GAL1, rat GAL1, human GAL2, rat GAL2, human GAL3 and rat GAL3 respectively .

HY-P3019

Urocortin III (human)	CRFR	Cardiovascular Disease Neurological Disease Endocrinology
Urocortin III (human) is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) selectively binds to type 2 CRF receptors with K_i values of 13.5, 21.7, and >100 nM for mCRF2β, rCRF2α, and hCRF1, respectively. Urocortin III (human) mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion .

HY-P3375

Mazdutide IBI-362; LY-3305677; OXM-3	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) .

HY-P3375A

Mazdutide TFA IBI-362 TFA; LY-3305677 TFA; OXM-3 TFA	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide TFA binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) .

HY-P1944

Apelin-13	Apelin Receptor (APJ)	Cardiovascular Disease Metabolic Disease
Apelin-13 is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC₅₀ value of 0.37 nM. Apelin-13 is widely distributed in the central and peripheral nervous systems. Apelin-13 has vasodilatory and antihypertensive effects. Apelin-13 also can be used for researching type 2 diabetes and metabolic syndrome .

Cat. No.	Product Name	Target	Research Area

HY-P99665

Insulin efsitora alfa LY-3209590	Insulin Receptor	Metabolic Disease
Insulin efsitora alfa (LY-3209590) is a selective agonist of insulin receptor (IR). Insulin efsitora alfa is a fusion protein composed of human IR agonists fused with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2) fragment, with a molecular weight of 64.1 kDa. Insulin efsitora alfa is well tolerated and has potential applications in diabetes .

HY-P990084

Veligrotug	IGF-1R	Cancer
Veligrotug is an IgG1-kappa, anti-IGF1R (insulin-like growth factor 1 receptor, CD221) chimeric monoclonal antibody .

HY-P99218

Robatumumab Sch 717454; 19D12	IGF-1R	Cancer
Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research .

HY-P99197

Figitumumab CP-751871	IGF-1R	Cancer
Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC₅₀ of 1.8 nM .

HY-P99530

Valanafusp alfa AGT-181; HIRMAb-IDUA	Insulin Receptor	Metabolic Disease
Valanafusp alfa (AGT-181) is a chimeric monoclonal antibody that fuses human α-L-iduronidase (IDUA) and targets the human insulin receptor (HIR). Valanafusp alfa has brain penetrating properties, making it useful for research on mucopolysaccharidosis type I (MPS I) .

HY-P99294

Ganitumab AMG 479; Human Anti-IGF1R Recombinant Antibody	IGF-1R	Cancer
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (K_D=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer .

HY-P990867

*Anti-CD220/Insulin* Receptor Antibody (IR 83-22)**	Inhibitory Antibodies	Others
Anti-CD220/Insulin Receptor Antibody (IR 83-22) is a kind of mouse IgG1 chimeric antibody, targeting to human CD220/Insulin Receptor. The recommend isotype control of Anti-CD220/Insulin Receptor Antibody (IR 83-22): Mouse IgG1 kappa, Isotype Control (HY-P99977).

HY-P990712

Ersodetug	Inhibitory Antibodies	Inflammation/Immunology
Ersodetug is an anti-INSR (insulin receptor) human IgG2 κ monoclonal antibody . Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).

Recombinant Proteins Recommended:

Species:	Human (11)
Tag:	His (8) Strep (1) GST (3) Fc (1)
Source:	HEK293 (6) Sf9 insect cells (2) E. coli (3)

Cat. No.	Compare	Product Name	Species	Source

HY-P73873

	Insulin R/CD220 Protein, Human (HEK293, His) CD 220; HHF5; INSR; Insulin R; Insulin receptor; IR	Human	HEK293
	The insulin R/CD220 protein is a receptor tyrosine kinase that coordinates insulin action by phosphorylating substrates such as IRS and SHC upon insulin binding. Phosphorylated IRS activates PI3K-AKT/PKB to exert metabolic effects, and activates Ras-MAPK to promote growth and differentiation. Insulin R/CD220 Protein, Human (HEK293, His) is the recombinant human-derived Insulin R/CD220 protein, expressed by HEK293 , with C-His labeled tag.

HY-P73244

	Insulin R/CD220 Protein, Human (sf9, His-GST) CD 220; HHF5; INSR; Insulin R; Insulin receptor; IR	Human	Sf9 insect cells
	The insulin R/CD220 protein is a receptor tyrosine kinase that coordinates insulin action by phosphorylating substrates such as IRS and SHC upon insulin binding. Phosphorylated IRS activates PI3K-AKT/PKB to exert metabolic effects, and activates Ras-MAPK to promote growth and differentiation. Insulin R/CD220 Protein, Human (sf9, His-GST) is the recombinant human-derived Insulin R/CD220 protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

HY-P77515

	Insulin R/CD220 Protein, Human (Biotinylated, HEK293, His) CD 220; HHF5; INSR; Insulin R; Insulin receptor; IR	Human	HEK293
	The insulin R/CD220 protein is a receptor tyrosine kinase that coordinates insulin action by phosphorylating substrates such as IRS and SHC upon insulin binding. Phosphorylated IRS activates PI3K-AKT/PKB to exert metabolic effects, and activates Ras-MAPK to promote growth and differentiation. Insulin R/CD220 Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived Insulin R/CD220 protein, expressed by HEK293 , with C-His labeled tag.

HY-P73873A

	Insulin R/CD220 Protein, Human (HEK293, C-His) CD 220; HHF5; INSR; Insulin R; Insulin receptor; IR	Human	HEK293
	The insulin R/CD220 protein is a receptor tyrosine kinase that coordinates insulin action by phosphorylating substrates such as IRS and SHC upon insulin binding. Phosphorylated IRS activates PI3K-AKT/PKB to exert metabolic effects, and activates Ras-MAPK to promote growth and differentiation. Insulin R/CD220 Protein, Human (HEK293, C-His) is the recombinant human-derived Insulin R/CD220 protein, expressed by HEK293 , with C-10*His labeled tag. The total length of Insulin R/CD220 Protein, Human (HEK293, C-His) is 929 a.a., with molecular weight of ~130 kDa.

HY-P72256

	IGF-I R Protein, Human (His) CD221; CD221 antigen ; IGF 1 receptor; IGF 1R; IGF I receptor; IGF-I receptor; Igf1r; IGF1R_HUMAN; IGFIR; IGFIRC; IGFR; Insulin like growth factor 1 receptor; Insulin like growth factor 1 receptor precursor; Insulin-like growth factor 1 receptor beta chain; Insulin-like growth factor I receptor; JTK13; MGC142170; MGC142172; MGC18216; Soluble IGF1R variant 1; Soluble IGF1R variant 2	Human	E. coli
	IGF-I receptor (IGF1R) mediates insulin-like growth factor effects, binding strongly to IGF1. Activation triggers PI3K-AKT/PKB and Ras-MAPK pathways, influencing cell survival, protein synthesis, and proliferation. IGF1R also signals through JAK/STAT, inhibiting JNK activation. Hybrid receptors show variable binding to IGF1 and insulin. IGF-I R Protein, Human (His) is the recombinant human-derived IGF-I R protein, expressed by E. coli , with N-6*His labeled tag. The total length of IGF-I R Protein, Human (His) is 169 a.a., with molecular weight of ~27 kDa.

HY-P72606

	IGF-I R Protein, Human (HEK293, His) Insulin-like growth factor 1 receptor; IGF-I receptor; IGF1R; CD221	Human	HEK293
	IGF-I receptor (IGF1R) mediates insulin-like growth factor effects, binding strongly to IGF1. Activation triggers PI3K-AKT/PKB and Ras-MAPK pathways, influencing cell survival, protein synthesis, and proliferation. IGF1R also signals through JAK/STAT, inhibiting JNK activation. Hybrid receptors show variable binding to IGF1 and insulin. IGF-I R Protein, Human (HEK293, His) is the recombinant human-derived IGF-I R protein, expressed by HEK293 , with C-6*His labeled tag. The total length of IGF-I R Protein, Human (HEK293, His) is 902 a.a., with molecular weight of 100-130 & 54 kDa, respectively.

HY-P74442

	IGF-I R Protein, Human (HEK293, His, solution) Insulin-like growth factor 1 receptor; IGF-I receptor; CD221; IGF1R	Human	HEK293
	IGF-I receptor (IGF1R) mediates insulin-like growth factor effects, binding strongly to IGF1. Activation triggers PI3K-AKT/PKB and Ras-MAPK pathways, influencing cell survival, protein synthesis, and proliferation. IGF1R also signals through JAK/STAT, inhibiting JNK activation. Hybrid receptors show variable binding to IGF1 and insulin. IGF-I R Protein, Human (HEK293, His, solution) is the recombinant human-derived IGF-I R protein, expressed by HEK293 , with C-His labeled tag.

HY-P702944

	IRS1 Protein, Human (GST) Insulin receptor substrate 1; IRS-1	Human	E. coli
	IRS1 Protein, Human (GST) is the recombinant human-derived IRS1, expressed by E. coli , with GST labeled tag. ,

HY-P703904

	Igf2r Protein, Human (hFc) Insulin like growth factor 2 receptor	Human	HEK293

HY-P73137

	IGF-I R Protein, Human (sf9, His-GST) Insulin-like growth factor 1 receptor; IGF-I receptor; CD221; IGF1R	Human	Sf9 insect cells
	IGF-I receptor (IGF1R) mediates insulin-like growth factor effects, binding strongly to IGF1. Activation triggers PI3K-AKT/PKB and Ras-MAPK pathways, influencing cell survival, protein synthesis, and proliferation. IGF1R also signals through JAK/STAT, inhibiting JNK activation. Hybrid receptors show variable binding to IGF1 and insulin. IGF-I R Protein, Human (sf9, His-GST) is the recombinant human-derived IGF-I R protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag. The total length of IGF-I R Protein, Human (sf9, His-GST) is 414 a.a., with molecular weight of ~74.6 kDa.

HY-P703573

	IRS1 Protein, Human (His, Strep) Insulin receptor substrate 1; IRS1; Homo sapiens; Human; IRS-1; Transducer	Human	E. coli
	IRS1 Protein, Human (His, Strep) is the recombinant human-derived IRS1, expressed by E. coli , with Strep, His labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-15656S

Ceritinib-d7
Ceritinib-d₇ is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor[1].

HY-15494S1

Picropodophyllin-d6
Picropodophyllin-d₆ (AXL1717-d₆) is deuterium labeled Picropodophyllin. Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80192

	Insulin Receptor Beta Antibody	WB, ICC/IF	Human, Rat
	Insulin Receptor Beta Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 156 kDa, targeting to Insulin Receptor Beta. It can be used for WB,ICC/IF assays with tag free, in the background of Human, Rat.

HY-P81795

	Insulin Receptor Antibody (YA1540) CD220; HHF5; human Insulin receptor; Insr; Insulin receptor subunit beta; IR 1; IR	WB, ICC/IF	Human, Rat
	Insulin Receptor Antibody (YA1540) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1540), targeting Insulin Receptor, with a predicted molecular weight of 156 kDa (observed band size: 95 kDa). Insulin Receptor Antibody (YA1540) can be used for WB, ICC/IF experiment in human, rat background.

HY-P80717

	IGF1 Receptor Antibody IGF1R; Insulin-like growth factor 1 receptor; Insulin-like growth factor I receptor; IGF-I receptor; CD antigen CD221	WB, IHC-P	Human
	IGF1 Receptor Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 155 kDa, targeting to IGF1 Receptor. It can be used for WB,IHC-P assays with tag free, in the background of Human.

HY-P80825

	Phospho-IGF1 Receptor (Tyr1166) Antibody IGF1R; Insulin-like growth factor 1 receptor; Insulin-like growth factor I receptor; IGF-I receptor; CD antigen CD221	WB, IP	Human, Mouse, Rat
	Phospho-IGF1 Receptor (Tyr1166) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 155 kDa, targeting to Phospho-IGF1 Receptor (Tyr1166). It can be used for WB,IP assays with tag free, in the background of Human, Mouse, Rat.

HY-P81754

	IGF2R Antibody (YA1499) IGF2R; MPRI; Cation-independent mannose-6-phosphate receptor; CI Man-6-P receptor; CI-MPR; M6PR; 300 kDa mannose 6-phosphate receptor; MPR 300; Insulin-like growth factor 2 receptor; Insulin-like growth factor II receptor; IGF-II receptor; M6P/IGF2 receptor; M6P/IGF2R; CD222	WB, IHC-P, ICC/IF, IP, FC	Human, Mouse, Rat
	IGF2R Antibody (YA1499) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1499), targeting IGF2R, with a predicted molecular weight of 274 kDa (observed band size: 274 kDa). IGF2R Antibody (YA1499) can be used for WB, IHC-P, ICC/IF, IP, FC experiment in human, mouse, rat background.

HY-P82526

	IRS2 Antibody (YA2271) Insulin receptor substrate 2; IRS 2; IRS-2	WB, IHC-P, ICC/IF, FC	Human, Mouse, Rat
	IRS2 Antibody (YA2271) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2271), targeting IRS2, with a predicted molecular weight of 137 kDa (observed band size: 185 kDa). IRS2 Antibody (YA2271) can be used for WB, IHC-P, ICC/IF, FC experiment in human, mouse, rat background.

HY-P81116

	IRS1 Antibody IRS1_HUMAN; Insulin receptor substrate 1; IRS-1; IRS 1	WB, ELISA, IHC-P, IHC-F, ICC/IF	Human, Mouse, Rat
	IRS1 Antibody is an unconjugated, approximately 137 kDa, rabbit-derived, anti-IRS1 polyclonal antibody. IRS1 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, rat and predicted: chicken background without labeling.

HY-P80193

	Insulin Receptor R Antibody	WB, IHC-P	Human, Mouse
	Insulin Receptor R Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 144 kDa, targeting to Insulin Receptor R. It can be used for WB,IHC-P assays with tag free, in the background of Human, Mouse.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-153479

Aganirsen		Antisense Oligonucleotides
Aganirsen is a 25 mer DNA antisense oligonucleotide, which silences expression of insulin receptor substrate-1 (IRS-1).

HY-153479A

Aganirsen sodium		Antisense Oligonucleotides
Aganirsen sodium is a 25 mer DNA antisense oligonucleotide, which silences expression of insulin receptor substrate-1 (IRS-1).

HY-153485A

Cimdelirsen sodium ISIS 766720 sodium; IONIS-GHR-LRx sodium		Antisense Oligonucleotides
Cimdelirsen is a novel, ligand-conjugated, hepatic-targeted investigative antisense oligonucleotide designed to reduce *growth hormone receptor* (GHr)** synthesis, thereby inhibiting deleterious effects of growth hormone (GH) hypersecretion and reducing circulating insulin-like growth factor-1 (IGF-1) levels in acromegaly patients.

HY-153485

Cimdelirsen ISIS 766720; IONIS-GHR-LRx		Antisense Oligonucleotides
Cimdelirsen is a novel, ligand-conjugated, hepatic-targeted investigative antisense oligonucleotide designed to reduce *growth hormone receptor* (GHr)** synthesis, thereby inhibiting deleterious effects of growth hormone (GH) hypersecretion and reducing circulating insulin-like growth factor-1 (IGF-1) levels in acromegaly patients.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks